What is Viracta Therapeutics 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-20), Viracta Therapeutics's 12-1 Month Momentum % is -59.68%.
The industry rank for Viracta Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
VIRX's 12-1 Month Momentum % is ranked worse than 68.94% of 1481
companies
in the Biotechnology industry
Industry Median: -26.15
vs VIRX: -59.68
Competitive Comparison of Viracta Therapeutics's 12-1 Month Momentum %
For the Biotechnology subindustry, Viracta Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Viracta Therapeutics 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Viracta Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Viracta Therapeutics (Viracta Therapeutics) Business Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIRX has been successfully added to your